U.S. Wearable Medical Devices Market to Reach USD 44.0 Billion by 2033 as Continuous Glucose Monitoring Adoption Broadens, Reports Epignosis Insights

Epignosis Insights has released new research on the U.S. Wearable Medical Devices Market, covering volume analysis, technology innovation, and the competitive landscape through 2033. According to the report, the U.S. wearable medical devices market recorded a sales volume of 30.5 million units in 2025 and is projected to grow from 27 million units in 2024 to 88 million units by 2033, registering a CAGR of 14.4% in volume terms. In value, the market is forecast to reach USD 44.0 billion by 2033, expanding at a CAGR of 16.2% during 2027-2033, as average selling prices rise from USD 430 to USD 500 per unit on the back of AI-enabled and clinically advanced devices.

Get Full Access of Report @https://epignosisinsights.com/report/us-wearable-medical-devices-market

CGM Expansion Drives the U.S. Wearable Medical Devices Market

The report identifies continuous glucose monitoring (CGM) as the largest and fastest-growing revenue contributor to the U.S. wearable medical devices market, as adoption broadens well beyond intensive insulin users. With over 38 million Americans living with diabetes and around 97 million adults classified as prediabetic, expanded Medicare CGM eligibility - mirrored by commercial insurers - has significantly widened the addressable patient population for manufacturers including Abbott and Dexcom. Next-generation CGMs now integrate with smartphone apps, cloud analytics, insulin delivery systems, and electronic health records, with sensor wear time extending to 14-15 days, reinforcing CGM's role as a comprehensive digital disease management platform within the U.S. wearable medical devices market.

Manufacturing Costs for Advanced Biosensors Remain a Key Constraint

The report finds that high manufacturing costs for advanced biosensors and semiconductor components remain a significant constraint on the U.S. wearable medical devices market. Semiconductor components account for 20-35% of the total bill of materials in advanced wearable monitors, with biosensors adding another 15-25%, while medical-grade MEMS sensors cost USD 8-25 per unit versus under USD 5 for consumer-grade equivalents. Specialized analog front-end chips used in ECG monitoring range from USD 10-40 each, and compliance with ISO 13485 and FDA Quality System Regulation requirements adds further per-unit cost, creating margin pressure especially for emerging MedTech entrants without economies of scale.

Outcomes-Based Reimbursement Reshapes Device Classification

A structural shift in insurance coverage is underway across the U.S. wearable medical devices market, the report notes, with the Centers for Medicare & Medicaid Services launching a decade-long ACCESS pilot that ties manufacturer payments to documented health outcomes rather than flat per-unit reimbursement. At the same time, employer-sponsored wellness programs from insurers including UnitedHealth Group, Humana, Cigna, and Highmark are emerging as a faster-growing adoption channel that bypasses formal FDA and CMS coverage criteria, with roughly two-thirds of Americans open to joining wearable-linked wellness programs given favorable incentives. Over-the-counter CGMs such as Dexcom Stelo and Abbott Lingo remain classified as wellness products eligible only for HSA/FSA reimbursement, distinct from prescription devices within the CMS framework.

Competitive Landscape

Companies profiled in the Epignosis Insights report as active participants in the U.S. wearable medical devices market include Abbott Laboratories, Dexcom, Medtronic, Apple, Boston Scientific, Masimo, GE HealthCare Technologies, iRhythm Technologies, AliveCor, BioIntelliSense, VitalConnect, WHOOP, Google (Fitbit/Google Health), Oura Health, and Koninklijke Philips, among others.

Epignosis Insights maps the competitive field through its proprietary Innovation x Market Presence positioning matrix, in which Apple, Abbott, and Dexcom occupy the narrow market-leaders quadrant, while private players Oura and WHOOP - valued at USD 11 billion and USD 10.1 billion respectively - stand out for innovation using FDA wellness exemptions to bring new features to market within the U.S. wearable medical devices market.

Outlook for the U.S. Wearable Medical Devices Market

Epignosis Insights expects pricing strategies to continue shifting toward outcome-driven service offerings as software, AI analytics, and cloud platforms contribute an increasing share of lifetime customer value beyond hardware sales. As reimbursement pathways expand and value-based healthcare models mature, the U.S. wearable medical devices market is positioned for sustained double-digit growth through 2033.

About the Report

The full report, "U.S. Wearable Medical Devices Market: Volume Analysis, Technology Innovation, Competitive Landscape, and Forecast to 2033," by Epignosis Insights provides detailed analysis by type (wrist-worn, chest-worn, head-worn, patch-based, ring, clothing and textile-based, ear-worn, and other wearable form factors), application, and end user, alongside competitive benchmarking.

Epignosis Insights
703 Kumar Corporate Building, Pune-411028, India
sales@epignosisinsights.com
Website: www.epignosisinsights.com

Follow connect us on LinkedIn: https://www.linkedin.com/company/epignosis-insights/

Epignosis Insights is a market research and consulting firm delivering data-driven analysis on emerging technology and agriculture markets worldwide. Combining primary interviews, secondary intelligence, and quantitative modeling, Epignosis Insights helps businesses, investors, and policymakers navigate high-growth sectors such as vertical farming, controlled-environment agriculture, and sustainable food production with confidence.

This release was published on openPR.